The increased geriatric population rates are driving the Taiwan in-vitro diagnostics market demand during the forecast period.

The Taiwan In-Vitro Diagnostics Market size was valued at USD 0.77 billion in 2023, and is predicted to reach USD 1.39 billion by 2030, at a CAGR of 8.4% from 2024 to 2030, according to new research by Next Move Strategy Consulting.

The significant rise in the geriatric’s population drives the growth of the in-vitro diagnostics market in the country. According to East Asia Forum, the proportion of Taiwan's population aged above 65 has surged from 2.5 percent in the 1950s to 17.56 percent in 2021. Projections by the National Development Council suggest that Taiwan will emerge as one of the world's oldest nations by 2060, with the elderly population comprising an estimated 41.4 percent of the total population. 

With a significant portion of the population entering older age, there is a heightened demand for diagnostic technologies to address age-related health issues and diseases. In particular, the prevalence of chronic conditions and age-related illnesses among the elderly population necessitates frequent monitoring, early detection, and personalized treatment approaches, all of which are facilitated by IVD solutions.

However, high costs associated with research, development, and regulatory approval are significant factors restraining the Taiwan in-vitro diagnostics market growth. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development. 

This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability. Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from the Taiwan in-vitro diagnostics market expansion.

On the other hand, point-of-care testing (POCT) is poised to be a significant driver of growth in the in-vitro diagnostics (IVD) market in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings. 

With POCT technologies offering rapid tests for infectious diseases, cardiac markers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions. 

By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.

Request for a sample here: https://www.nextmsc.com/taiwan-in-vitro-diagnostics-market/request-sample

Several key players operating in the Taiwan in-vitro diagnostics industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

Key Insights from the Taiwan In-Vitro Diagnostics Market Report:

• The information related to key drivers, restraints, and opportunities and their impact on the Taiwan in-vitro diagnostics market trends is provided in the report.

• The value chain analysis in the market study provides a clear picture of the roles of each stakeholder.

• The market share of players in the Taiwan in-vitro diagnostics market is provided in the report along with their competitive analysis.